文献速递泌尿生殖与妇科肿瘤放疗

宫颈癌的调强放疗与图像引导自适应近距离放疗

Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-11-14

本研究比较了宫颈癌患者接受调强放疗联合三维图像引导自适应近距离放疗(IMRT/3D-IGABT)与二维体外照射联合二维近距离放疗(2D EBRT/BT)的长期结局。IMRT/3D-IGABT组5年无复发生存率65% vs 57%(P=.04)、癌症特异性生存率69% vs 62%(P=.01)、总生存率61% vs 57%(P=.04),≥3级晚期肠/膀胱毒性11% vs 18%(P=.02)。

要点

  • IMRT/3D-IGABT较2D EBRT/BT改善5年无复发生存、癌症特异性生存和总生存。
  • IMRT/3D-IGABT组≥3级晚期肠/膀胱毒性11%,低于2D EBRT/BT组的18%(P=.02)。
  • 仅盆腔淋巴结阳性患者中,IMRT/3D-IGABT的疾病控制改善最明显(P=.02)。

核心结论

  • 与2D EBRT/BT相比,IMRT/3D-IGABT与宫颈癌患者生存改善及胃肠和泌尿生殖毒性降低相关。

研究设计与样本

  • 研究纳入1997年至2013年接受根治性放疗的新诊断宫颈癌患者,均具备治疗前氟脱氧葡萄糖正电子发射断层扫描。
  • 治疗政策于2005年从2D EBRT/BT改为IMRT/3D-IGABT。
  • 2D EBRT/BT组300例,IMRT/3D-IGABT组300例;评估复发模式、癌症特异性生存和总生存,晚期胃肠及泌尿生殖毒性采用美国国家癌症研究所常见不良事件术语标准评分。

主要发现

  • 2D EBRT/BT组末次随访时存活患者中位随访15.3年(范围10.8-20.5年),IMRT/3D-IGABT组为7年(范围5-12.4年)。
  • 按国际妇产科联盟分期,33%为IB1至IB2期,41%为IIA至IIB期,26%为IIIA至IVA期。
  • 2D EBRT/BT组5年无复发生存率57%、癌症特异性生存率62%、总生存率57%;IMRT/3D-IGABT组分别为65%(P=.04)、69%(P=.01)、61%(P=.04)。
  • 按正电子发射断层扫描淋巴结状态分层,仅盆腔淋巴结阳性患者中IMRT/3D-IGABT较2D EBRT/BT的疾病控制改善最明显(P=.02)。
  • 600例中88例(15%)发生≥3级晚期肠/膀胱毒性;2D EBRT/BT组55例(18%),IMRT/3D-IGABT组33例(11%;P=.02)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study reported long-term outcomes of patients with cervical cancer who were treated with intensity modulated radiation therapy and 3-dimensional (3D) image-guided adapted brachytherapy (IMRT/3D-IGABT) compared with those treated with 2-dimensional (2D) external irradiation and 2D brachytherapy (2D EBRT/BT). METHODS AND MATERIALS: This study included patients with newly diagnosed cervical cancer and pretreatment fluorodeoxyglucose positron emission tomography scans who were treated with curative-intent irradiation from 1997 to 2013. The treatment policy changed from using 2D EBRT/BT to IMRT/3D-IGABT in 2005. Patterns of recurrence, cancer-specific survival (CSS), and overall survival (OS) were evaluated. Late gastrointestinal and genitourinary toxicity were scored with National Cancer Institute Common Terminology Criteria for Adverse Events. RESULTS: The median follow-up for patients alive at the time of last follow-up in the 2D EBRT/BT group (n = 300) was 15.3 years (range, 10.8-20.5 years). In the IMRT/3D-IGABT group (n = 300), it was 7 years (range, 5-12.4 years). According to the International Federation of Gynecology and Obstetrics, 33% of tumors were stage IB1 to IB2, 41% were stage IIA to IIB, and 26% were stage IIIA to IVA. The results after 5 years for patients treated with 2D EBRT/BT showed that freedom from relapse (FFR) was 57%, CSS was 62%, and OS was 57%. For the IMRT/3D-IGABT group, the 5-year results showed that FFR was 65% (P = .04), CSS was 69% (P = .01), and OS was 61% (P = .04). When stratified by lymph node status according to positron emission tomography scan results, disease control was most improved with IMRT/3D-IGABT versus 2D EBRT/BT in patients with positive pelvic lymph nodes only (P = .02). Cumulatively, 88 of 600 patients (15%) had grade ≥3 late bowel/bladder toxicity. The 2D EBRT/BT group had 55 patients (18%), and the IMRT/3D-IGABT group had 33 patients (11%; P = .02). CONCLUSIONS: IMRT/3D-IGABT was associated with improved survival and decreased gastrointestinal and genitourinary toxicity in patients with cervical cancer compared with those who received 2D EBRT/BT.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Lin AJ, Kidd E, Dehdashti F, et al. Intensity Modulated Radiation Therapy and Image-Guided Adapted Brachytherapy for Cervix Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 30445171. doi:10.1016/j.ijrobp.2018.11.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。